NanoViricides Inc
0.86 %
3.54 %
Yet to be announced
Company Overview
NanoViricides Inc is a development-stage biopharmaceutical company focused on creating nanomedicine solutions for viral diseases. The company develops novel nanomedicines designed to attack viruses by binding to them and neutralizing them. Their primary focus is on developing treatments for various viral infections including influenza, HIV/AIDS, herpes, dengue fever, and COVID-19.
The company is currently in pre-revenue stage, focusing on research and development of their drug candidates. They operate primarily through their facility in Shelton, Connecticut, where they conduct their research and development activities.
Revenue Sources
PassAs NanoViricides is a pre-revenue company focused on research and development of antiviral medications, with zero revenue over the past four quarters, this criterion is not applicable at this stage. The company's planned revenue sources from potential future drug sales would be halal.
Reliance on Interest
| Reporting Date | Total Revenue | Total Expense | Interest Income | Interest Expense | Interest Income Ratio | Interest Expense Ratio |
|---|
The company is pre-revenue and still in research and development phase. Over the past four quarters, interest expense has been minimal or zero, with only one quarter showing a small interest expense of $13,315. Given the company's pre-revenue status, the interest ratios are not meaningful indicators at this stage of development.
Operational Ethics
PassBased on available information from SEC filings and company disclosures, NanoViricides does not maintain any significant ongoing associations with entities involved in human rights violations. The company's primary operations are based in the United States, and there is no evidence of material relationships with the state of Israel or the Chinese Communist Party.
Comments